Toronto, Ontario–(Newsfile Corp. – May 31, 2022) – Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” Where “TELO”) announces that it has completed validation of a suite of proprietary automation tools developed using cutting-edge machine learning, deep machine learning and artificial intelligence technologies to maximize the efficiency and throughput of its technology workflow. Validation was conducted on a subset of smoldering multiple myeloma (SMM) patient samples received in collaboration with Center de cancérologie François Baclesse, Caen, France.
TELO recently completed a series of projects with the goal of automating and improving the accuracy and efficiency of its new diagnostic platform. These projects included: i) increased automation and batch processing of the microscopy aspects of the assay, ii) development of machine learning and artificial intelligence algorithms to facilitate automated selection of target cells, a key step in single cell analysis which enriches the value of TeloView analysis, and iii) enhanced the processing capability of the TeloView platform.
Implementing these automation tools is expected to increase TeloView workflow efficiency and productivity by more than 40%. The main benefits of these improvements include: i) reduced sample processing time, ii) simplified and less operator dependent processes leading to higher accuracy, iii) reduced labor costs and iv ) a net reduction in sample processing steps. In short, the developed automation toolset will reduce test turnaround time, a key value enhancement driver that will drive adoption of the technology in the clinic.
“The development of these proprietary automation tools is an important step that positions the TeloView platform as an efficient, world-class technology,” said Sherif Louis, CEO of TELO. “Adopting these tools into our workflow provides key advancements as TELO pursues clinical studies, industry partnership and a host of new business opportunities.”
Validation results have been reviewed and approved by the company’s science and technology committee and automation tools are being implemented to accelerate timelines for ongoing clinical studies in collaboration with Mayo Clinic to develop the lead product of TELO for SMM patients.
About Smoldering Multiple Myeloma
MMS is a biological precursor to multiple myeloma, a deadly cancer that forms in plasma cells, a type of white blood cell. Typically, SMM is asymptomatic, but about 15% of patients with SMM progress to active multiple myeloma, which involves marked pain, the risk of bone fractures, and other debilitating symptoms. To date, identifying high-risk SMM patients who will benefit from immediate therapeutic intervention, and confirming disease stability of low-risk SMM patients who can be safely monitored over time, remains a challenge. key unmet clinical need in the management of multiple myeloma. The total addressable market for this TeloView test is conservatively estimated at over 200,000 SMM patients in the United States alone, with the potential for over 500,000 tests per year.
Telo Genomics Corp. is a biotechnology company pioneering the industry’s most comprehensive telomere platform with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of considerable interest to the medical community because it is less invasive and more easily reproducible than traditional diagnostic approaches. By combining our team’s considerable expertise in quantitative 3D telomere analysis with molecular biology and artificial intelligence to recognize genetic instability associated with disease, TELO develops simple and accurate products that improve the daily care of patients by meeting the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been confirmed in over 160 peer-reviewed publications and in over 30 clinical studies involving over 3,000 patients with multiple cancers and Alzheimer’s disease. Our main application, TELO-MM, is being developed to provide important and actionable information to healthcare professionals in the treatment of multiple myeloma, a deadly form of blood cancer. For more information, visit www.telodx.com.
For more information, please contact:
MaRS Center, South Tower,
101 College Street, Suite 200,
Toronto, Ontario M5G 1L7
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Statements
Certain information contained herein may constitute “forward-looking information” under Canadian securities laws. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “intends”, “will”, or variations of these words and phrases or statements that certain actions, events or results “will happen”. Forward-looking statements regarding the clinical effectiveness of the products, the commercial viability of the products, the use of benefits and the ability of TeloView® platform to provide personalized medicine resulting in better treatments and outcomes are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, the level of activity, performance or achievements of the Company are materially different from those expressed or implied by such forward-looking statements or information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information incorporated by reference herein, except as required by applicable securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/125907